AN2 Therapeutics
a phase pivotal clinical trial of in treatment refractory mac lung disease plan to use pathway in microbiological primary in japan to support potential registration phase part phase part an therapeutics | AN2 Therapeutics
Deck date
August 2022
Slide
18 of 25
Similar slides by AN2 Therapeutics
IPO
March 2022
Related slides by other companies
Investor Presentation
November 2024
Investor Presentation
December 2024
Investor Presentation
March 2023
Investor Presentation
November 2023
Other recent decks by AN2 Therapeutics
Investor Presentation
March 2025
Investor Presentation
February 2025
IPO
March 2022
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io